Clinical Trial Detail

NCT ID NCT03840200
Title A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Recruitment Not yet recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Hoffmann-La Roche
Indications

fallopian tube cancer

peritoneum cancer

prostate adenocarcinoma

endometrioid ovary carcinoma

ovarian clear cell carcinoma

ovarian serous carcinoma

Her2-receptor negative breast cancer

Therapies

Ipatasertib + Rucaparib

Age Groups: adult senior

Additional content available in CKB BOOST